S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
LON:AMYT

Amryt Pharma (AMYT) Share Price, News & Analysis

Today's Range
N/A
50-Day Range
143
143
52-Week Range
N/A
Volume
90,727 shs
Average Volume
469,552 shs
Market Capitalization
£457.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AMYT stock logo

About Amryt Pharma Stock (LON:AMYT)

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

AMYT Stock News Headlines

Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Amryt Supports Acromegaly Awareness Day 2022
AMYT Amryt Pharma plc
Amryt Pharma PLC ADR Stock Quote AMYT
Amryt Announces New Patent for Mycapssa®
Amryt Pharma PLC Rings the Opening Bell
See More Headlines
Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£210.24 million
Book Value
GBX 96.60 per share

Miscellaneous

Free Float
N/A
Market Cap
£457.11 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Joseph A. Wiley (Age 50)
    CEO & Director
    Comp: $1.72M
  • Mr. Rory P. Nealon (Age 53)
    CFO, COO & Company Sec.
    Comp: $931k
  • Ms. Elizabeth Varki Jobes J.D. (Age 54)
    Sr. VP & Global Chief Compliance Officer
  • Mr. John McEvoy
    Gen. Counsel
  • Mr. Stephen Joyce
    VP of Global Marketing
  • Ms. Julie Eastwood
    Head of HR
  • Ms. Derval O'Carroll
    Head of Regulatory Affairs
  • Mr. Gerry Gilligan
    Head of Manufacturing Supply Chain
  • Dr. Mark Sumeray (Age 55)
    Chief Medical Officer
  • Mr. David Allmond
    Chief Commercial Officer

AMYT Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), Concepta PLC (CPT.L) (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL), Bowleven (BLVN), BTG (BTG) and Cavium (CAVM).

How do I buy shares of Amryt Pharma?

Shares of AMYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AMYT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners